These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

245 related items for PubMed ID: 11380644

  • 21. Controlled comparison of nefazodone and amitriptyline in major depressive inpatients.
    Ansseau M, Darimont P, Lecoq A, De Nayer A, Evrard JL, Krémer P, Devoitille JM, Dierick M, Mertens C, Mesotten F.
    Psychopharmacology (Berl); 1994 Jun; 115(1-2):254-60. PubMed ID: 7862904
    [Abstract] [Full Text] [Related]

  • 22. Tolerability and safety: essentials in antidepressant pharmacotherapy.
    Lader MH.
    J Clin Psychiatry; 1996 Jun; 57 Suppl 2():39-44. PubMed ID: 8626362
    [Abstract] [Full Text] [Related]

  • 23. Nefazodone in the treatment of premenstrual syndrome: a preliminary study.
    Freeman EW, Rickels K, Sondheimer SJ, Denis A, Pfeifer S, Weil S.
    J Clin Psychopharmacol; 1994 Jun; 14(3):180-6. PubMed ID: 8027414
    [Abstract] [Full Text] [Related]

  • 24. Three- to four-year follow-up to an open trial of nefazodone for combat-related posttraumatic stress disorder.
    Hertzberg MA, Feldman ME, Beckham JC, Moore SD, Davidson JR.
    Ann Clin Psychiatry; 2002 Dec; 14(4):215-21. PubMed ID: 12630657
    [Abstract] [Full Text] [Related]

  • 25. Response of anxiety and agitation symptoms during nefazodone treatment of major depression.
    Fawcett J, Marcus RN, Anton SF, O'Brien K, Schwiderski U.
    J Clin Psychiatry; 1995 Dec; 56 Suppl 6():37-42. PubMed ID: 7649972
    [Abstract] [Full Text] [Related]

  • 26. An open-label study of nefazodone in the treatment of depression with and without comorbid obsessive compulsive disorder.
    Nelson EC.
    Ann Clin Psychiatry; 1994 Dec; 6(4):249-53. PubMed ID: 7647834
    [Abstract] [Full Text] [Related]

  • 27. Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial.
    Silberstein SD, Lipton RB, Dodick DW, Freitag FG, Ramadan N, Mathew N, Brandes JL, Bigal M, Saper J, Ascher S, Jordan DM, Greenberg SJ, Hulihan J, Topiramate Chronic Migraine Study Group.
    Headache; 2007 Feb; 47(2):170-80. PubMed ID: 17300356
    [Abstract] [Full Text] [Related]

  • 28. Effectiveness and safety of tapentadol prolonged release for severe, chronic low back pain with or without a neuropathic pain component: results of an open-label, phase 3b study.
    Steigerwald I, Müller M, Davies A, Samper D, Sabatowski R, Baron R, Rozenberg S, Szczepanska-Szerej A, Gatti A, Kress HG.
    Curr Med Res Opin; 2012 Jun; 28(6):911-36. PubMed ID: 22443293
    [Abstract] [Full Text] [Related]

  • 29. Cervical non-invasive vagus nerve stimulation (nVNS) for preventive and acute treatment of episodic and chronic migraine and migraine-associated sleep disturbance: a prospective observational cohort study.
    Kinfe TM, Pintea B, Muhammad S, Zaremba S, Roeske S, Simon BJ, Vatter H.
    J Headache Pain; 2015 Jun; 16():101. PubMed ID: 26631234
    [Abstract] [Full Text] [Related]

  • 30. OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program.
    Aurora SK, Winner P, Freeman MC, Spierings EL, Heiring JO, DeGryse RE, VanDenburgh AM, Nolan ME, Turkel CC.
    Headache; 2011 Oct; 51(9):1358-73. PubMed ID: 21883197
    [Abstract] [Full Text] [Related]

  • 31. Efficacy and tolerability of once-daily OROS hydromorphone and twice-daily extended-release oxycodone in patients with chronic, moderate to severe osteoarthritis pain: results of a 6-week, randomized, open-label, noninferiority analysis.
    Hale M, Tudor IC, Khanna S, Thipphawong J.
    Clin Ther; 2007 May; 29(5):874-888. PubMed ID: 17697906
    [Abstract] [Full Text] [Related]

  • 32. Reemergence of sexual dysfunction in patients with major depressive disorder: double-blind comparison of nefazodone and sertraline.
    Ferguson JM, Shrivastava RK, Stahl SM, Hartford JT, Borian F, Ieni J, McQuade RD, Jody D.
    J Clin Psychiatry; 2001 Jan; 62(1):24-9. PubMed ID: 11235924
    [Abstract] [Full Text] [Related]

  • 33. Nefazodone: a new antidepressant.
    Ellingrod VL, Perry PJ.
    Am J Health Syst Pharm; 1995 Dec 15; 52(24):2799-812. PubMed ID: 8748566
    [Abstract] [Full Text] [Related]

  • 34. Transdermal buprenorphine patches applied in a 4-day regimen versus a 3-day regimen: a single-site, Phase III, randomized, open-label, crossover comparison.
    Likar R, Lorenz V, Korak-Leiter M, Kager I, Sittl R.
    Clin Ther; 2007 Aug 15; 29(8):1591-606. PubMed ID: 17919542
    [Abstract] [Full Text] [Related]

  • 35. Sexual function and satisfaction in the treatment of chronic major depression with nefazodone, psychotherapy, and their combination.
    Zajecka J, Dunner DL, Gelenberg AJ, Hirschfeld RM, Kornstein SG, Ninan PT, Rush AJ, Thase ME, Trivedi MH, Arnow BA, Borian FE, Manber R, Keller MB.
    J Clin Psychiatry; 2002 Aug 15; 63(8):709-16. PubMed ID: 12197452
    [Abstract] [Full Text] [Related]

  • 36. A randomized, double-blind controlled comparison of nefazodone and paroxetine in the treatment of depression: safety, tolerability and efficacy in continuation phase treatment.
    Baldwin DS, Hawley CJ, Mellors K, CN104-070 Study Group.
    J Psychopharmacol; 2001 Sep 15; 15(3):161-5. PubMed ID: 11565622
    [Abstract] [Full Text] [Related]

  • 37. Nefazodone in the adjunctive therapy of schizophrenia: an open-label exploratory study.
    Rosenberg PB, Rosse RB, Schwartz BL, Deutsch SI.
    Clin Neuropharmacol; 2000 Sep 15; 23(4):222-5. PubMed ID: 11020129
    [Abstract] [Full Text] [Related]

  • 38. Botulinum toxin type a for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled study.
    Dodick DW, Mauskop A, Elkind AH, DeGryse R, Brin MF, Silberstein SD, BOTOX CDH Study Group.
    Headache; 2005 Apr 15; 45(4):315-24. PubMed ID: 15836567
    [Abstract] [Full Text] [Related]

  • 39. Treatment of chronic daily headache with comorbid anxiety and depression using botulinum toxin A: a prospective pilot study.
    Zhang H, Zhang H, Wei Y, Lian Y, Chen Y, Zheng Y.
    Int J Neurosci; 2017 Apr 15; 127(4):285-290. PubMed ID: 27439999
    [Abstract] [Full Text] [Related]

  • 40. Nefazodone in social phobia.
    Van Ameringen M, Mancini C, Oakman JM.
    J Clin Psychiatry; 1999 Feb 15; 60(2):96-100. PubMed ID: 10084635
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.